Loading organizations...
§ Private Profile · Los Gatos, CA, USA
Biotech company developing rapid diagnostic technology for multidrug-resistant bacteria and antibiotic susceptibility testing.
GeneWEAVE Biosciences is a biotechnology company that develops advanced diagnostic technology for the rapid identification of multidrug-resistant bacteria and antibiotic susceptibility testing directly from raw clinical samples. The enterprise utilizes a proprietary approach to bypass traditional culture and preparation methods, aiming to address antibiotic-resistant infections that cause approximately 2 million illnesses and 25,000 deaths annually in the United States. Operating as a venture-backed startup, the firm received early financial backing from lead investor XSeed Capital to commercialize its diagnostic platforms for hospitals and clinical healthcare providers. The organization was subsequently acquired by global healthcare corporation Roche, integrating its technology into a broader portfolio of clinical diagnostic solutions under the leadership of chief executive officer Steve Tablak. GeneWEAVE was originally founded as a private enterprise by entrepreneurs Diego Rey, Jason Springs, and Leonardo Maestri Teixeira.
GeneWEAVE has raised $24.0M across 2 funding rounds.
GeneWEAVE has raised $24.0M in total across 2 funding rounds.
GeneWEAVE has raised $24.0M in total across 2 funding rounds.
GeneWEAVE's investors include Decheng Capital, Claremont Creek Ventures, XSeed Capital, Min Cui, Ted Driscoll.
GeneWEAVE has raised $24.0M across 2 funding rounds. Most recently, it raised $12.0M Other Equity in July 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 2, 2014 | $12M Venture Round | Decheng Capital | Claremont Creek Ventures, XSeed Capital | Announced |
| Feb 28, 2012 | $12M Series A | MIN CUI | TED Driscoll, XSeed Capital | Announced |